In celebration of this milestone, we are pleased to announce that, in addition to the annual Oncology Award, we will be introducing a one-time special Hematology Award. This special award underscores our commitment to advancing care in both oncology and hematology. We look forward to continuing this journey together, fostering a future where cancer care is more effective and accessible for all.
WHAT IS IT ABOUT?
The annual Pfizer Oncology Award is intended to support, recognise and encourage one innovative project in Belgium or Luxembourg that improves the quality or additionally the availability of patient care in oncology.
To mark the 10th anniversary of the Pfizer Oncology Award, we will be awarding two projects this year. In 2025, Pfizer SA/NV will grant one “Pfizer Oncology Award” valued at €20,000 and a one-time special “Pfizer Hematology Award” also valued at €20,000 to innovative projects focusing on patient care in Belgium and/or Luxembourg. The Hematology Award is similar to the Oncology Award but specifically focuses on projects that benefit hematology patients.
FOR WHICH PROJECT?
The Pfizer Oncology Award and Pfizer Hematology Award are open to projects that aim to improve the quality and/or availability of patient care in oncology and hematology, respectively.
Eligible projects can be related to new ways of collaboration and organisation between various healthcare providers or different levels of care throughout the course of the disease. Projects must be in the conceptual or design phase and start within a year of receiving the award. Fundamental, translational and commercial clinical drug trials are out of scope.
WHO CAN SUBMIT?
The project must be realized in collaboration with a hospital, network of hospital, university, certified medical center or registered scientific society in Belgium or Luxembourg. We welcome submissions from healthcare professionals and all members of the multidisciplinary team, favoring comprehensive and collaborative patient care.
An independent Scientific Committee has developed a set of rules, including predefined selection criteria, to select the winning projects. For all details, please refer to the rules.
WHO’S THE SCIENTIFIC COMMITTEE?
PROF. SYLVIE ROTTEY, MD, PhD
Medical Oncologist, Clinical Pharmacologist
Head of the department of Medical Oncology Gent University Hospital
Head of the Drug Research Unit GentDR. GUY BERCHEM MD, PhD
Medical Oncologist, Head
Oncology Platform Centre Hospitalier de Luxembourg (CHL) President Luxembourg National Institute of Cancer (INC)MR. PATRICK CROMBEZ RN, AOCNS, MSCN, MHCM, MMCA
Head Nurse Department
of Hematology Bordet Institute Brussels
President of the Belgian Oncology Nursing Society SIO
Executive Board Member European Oncology Nursing SocietyMR. SVEN D’HAESE, MSC
Coordinator of the Radiotherapy Department of UZ Brussel
Chairman of VVRO (Society for Radiotherapy and Oncology nurses)PROF. GUY JERUSALEM, MD, PhD
Head of Medical Oncology
CHU Sart Tilman LiegePROF. JEAN - FRANCOIS BAURAIN, MD, PhD
Head of Clinic
Responsible of melanoma Clinic
Cliniques universitaires Saint-Luc – BrusselsPROF. DR. HANS PRENEN
Head of Oncology department,
Head of Phase 1 - Clinical Trials
Universitair Ziekenhuis AntwerpenPROF. ANNE DEMOLS, MD, PhD
Department of Gastroenterology and Digestive Oncology,
Hôpital Erasme et Institut Jules Bordet, HUBPROF. PETER VANDENBERGHE, MD, PhD
Head of Department of Haematology,
UZ LeuvenDepartment of Human Genetics,
KU LeuvenDR. LORE DECOSTER, MD, PhD
Medical Oncology
UZ Brussel
HOW TO PARTICIPATE?
SUBMIT YOUR PROJECT
VIA THE ONLINE APPLICATION FORM
TAKE A LOOK
AT THE RULES